Endo Health’s New CEO Will Be Revealing His Strategy – Good News for Investors?
Chatter on the specialty pharma front is that Endo Health’s (ENDP) newly hired CEO will be shaking hands with shareholders in a multi-city road show over the next two weeks. We expect clarity from the new helmsman on how he plans to create shareholder value at Endo, whose stock and business have struggled over the last year.
Read more »OneMedPlac
Read more »Editor’s Note: March 22, 2013
OneMedPlace is pleased to kick off a new season of our weekly Sentinel as we gear up for the 4th […]
Read more »
Glysure CEO Discusses Real-Time Glucose Monitoring Technology, ISO 13485 Certification and CE Mark
As part of our expert series on the state of the industry, OneMedRadio spoke with Glysure CEO Chris Jones to discuss this recent news and learn about this unique technology. Jones also discussed trends in the industry affecting company growth and investment strategy, including reimbursement issues, evolving exit strategy, and the move away from normative medicine.
Read more »
OneMedRadio: Vijay Aggarwal Discusses Diagnostics Trends in 2013 (Part I)
As we approach mid-year, many questions raised in the past year surrounding the state of healthcare company growth development have […]
Read more »Amedisys Shares Are Too Pricey For A Declining Business: Looking for Single Digits
Amedisys, Inc. (AMED) reported 4Q and year-end earnings Tuesday, March 12, and the key highlight was the company’s 2013 EPS guidance range of $0.60-$0.70, substantially below the Street’s $0.77 estimate. Analysts EPS estimates were lowered when the company reported its third quarter 2012 earnings miss (2013 EPS forecasts back then called for $0.93 a share), hence, the business continues to deteriorate and the earnings trough has not yet been reached.
Read more »
Acadia Forges Forward With Pimavanserin
On March 12, 2013, Acadia Pharmaceuticals (ACAD) reported financial results for the fourth quarter and full year 2012. Total revenues in the quarter were $0.4 million, essentially in-line with our estimate of $0.3 million. Revenues consisted of collaborative payments from Allergan, Inc. (AGN) and other collaboration partners. For the full year 2012, total revenues were $4.9 million.
Read more » PDUFA: Kadcyla, Immunogen – Metastasized Breast Cancer
Metastasized breast cancer now has a new therapy on the market, though it remains to be seen whether noticeably dangerous side effects may prevent widespread use. Trastuzumab emtansine (T-DM1) or Kadcyla, produced by Immunogen [Nasdaq: IMGN], is a treatment that targets the HER2 protein.
Read more »Meaningful Use, The Affordable Care Act, Sequestration, and Medical Devices
The Healthcare ecosystem in the United States is changing dramatically due to significant regulations and legislation. Though Obamacare gets the most attention for its impact on patient care and healthcare coverage, legislation such as the Meaningful Use Regulations passed in 2009, followed by the passage of the Affordable Care Act in 2010, and the most recent Sequestration may have a profound impact on the opportunities for developing medical devices and medical device investors.
Read more »
RELEASE: Glysure Earns ISO 13485 Certification
GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, today announced that it has achieved ISO 13485 certification, the global standard for the requirements of a quality management system for the design, manufacture and distribution of medical devices. By establishing a quality management system that meets international regulatory and customer requirements, GlySure has set the foundation for its European clinical trials.
Read more »